Inquis Medical Announces $40 Million Series B Financing to Accelerate Advancement of Aventus Thrombectomy System Addressing Venus Thromboembolic Diseases
MENLO PARK, Calif.–(BUSINESS WIRE)–Inquis Medical, a pioneering medical technology company specializing in advanced thrombectomy systems, today announced the successful closure of its $40 million Series B financing round. This oversubscribed round was led by Marshall Wace, a globally recognized investment firm, with strong participation from existing investors, including ShangBay Capital, Yu Star, EnPointe Ventures, and Pierre Lamond. The funding positions Inquis Medical for significant growth and development as it advances its cutting-edge technologies and prepares for commercialization.